PEPFAR reauthorization 'rests with Congress,' OGAC official says

NewsGuard 100/100 Score

Speaking at a briefing on Tuesday at the Center for Strategic and International Studies (CSIS) in Washington, D.C., Deputy Global AIDS Coordinator Julia Martin said "[t]he decision about whether to reauthorize [PEPFAR] 'rests with Congress. ... Whether we move in that direction is yet to be fully determined but PEPFAR will continue at the will of Congress,'" CQ HealthBeat reports. "Many advocates assume that lawmakers are preoccupied with other international priorities and will not focus on PEPFAR enough to move a bill," the news service writes, adding, "Even without a reauthorization, the program can continue." The briefing, co-sponsored by CSIS and the Kaiser Family Foundation, focused on the Institute of Medicine's (IOM) Evaluation of PEPFAR, which was released in February, the news service notes. "Martin said at the briefing that federal officials can move forward with IOM recommendations without the need for legislation," CQ HealthBeat writes (Adams, 4/30). According to the event's webpage, J. Stephen Morrison, CSIS vice president and director of the CSIS Global Health Policy Center, moderated the panel, which included Martin; Chris Collins, vice president and director of public policy at amfAR, the Foundation for AIDS Research; Jennifer Kates, vice president and director of global health and HIV policy at the Kaiser Family Foundation; and Kimberly Scott, senior program officer at the Institute of Medicine (4/30).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer